Seven Eight Capital, LP Immunovant, Inc. Transaction History

Seven Eight Capital, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$25.1 - $31.61 $1.39 Million - $1.76 Million	-55,540 Reduced 84.01%	10,575 $279,000
Q1 2024 May 13, 2024	SELL	$30.27 - $43.79 $983,502 - $1.42 Million	-32,491 Reduced 32.95%	66,115 $2.14 Million
Q4 2023 Feb 13, 2024	BUY	$31.31 - $44.19 $1.67 Million - $2.35 Million	53,200 Added 117.17%	98,606 $4.15 Million
Q3 2023 Nov 14, 2023	SELL	$18.55 - $39.96 $8,681 - $18,701	-468 Reduced 1.02%	45,406 $1.74 Million
Q2 2023 Aug 14, 2023	BUY	$14.2 - $23.75 $651,410 - $1.09 Million	45,874 New	45,874 $870,000

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.